TIDMVEC

RNS Number : 3481F

Vectura Group plc

17 May 2017

Vectura Group plc

Notice of Capital Markets Event

Chippenham, UK, 17 May 2017: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways disease focused business, will hold a Capital Markets Event in London for analysts and investors in the afternoon, Wednesday 28 June 2017.

The agenda will focus on Vectura's unique integrated inhaled drug development platform and will include a pipeline overview. James Ward-Lilley, Chief Executive Officer, will host the event with members of the Executive Leadership and senior management teams.

Invitations and a detailed agenda will follow in due course. The venue will be Etc. Venues, Fenchurch Street, 8 Fenchurch Place, London, EC3M 4PB.

- ENDS -

Enquiries

 
Vectura Group plc                                                +44 (0)1249 667700 
Andrew Derodra - Chief Financial Officer 
Fleur Wood - Director Communications 
Elizabeth Knowles - Director Investor Relations and Analysis 
 
Consilium Strategic Communications                               +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson                  vectura@consilium-comms.com

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and "smart" nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCGGUGPAUPMGMQ

(END) Dow Jones Newswires

May 17, 2017 02:00 ET (06:00 GMT)

Vectura (LSE:VEC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Vectura Charts.
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Vectura Charts.